Biomea Fusion (NASDAQ:BMEA) Bolsa, Quote.MetaTitle.unusual-options

Biomea Fusion

Biomea Fusion Inc

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Clene

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

InflaRx

Immix Biopharma

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Macrogenics

Metagenomi

OKYO Pharma

Ovid Therapeutics

Quince Therapeutics

AVITA Medical

Sutro Biopharma

Shattuck Labs

Instil Bio

Tevogen Bio Holdings

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Biomea Fusion (BMEA) Previsión

Noticias

Beneficios

Opciones

Calificaciones de analistas

Operaciones de insiders

Interés en corto

Informe de acciones

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Comments

Biomea Fusion Opciones Inusuales

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL